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Superparamagnetic   iron-doped  nanocrystalline 
apatite as a delivery system for doxorubicint 
Michele lafisco,*a Christophe Drouet,*b Alessio Adamiano ,a Patricia Pascaud,:j:b 
Monica Montesi,a Silvia Panseri,a Stephanie Sardab and Anna Tampieria 
The development of non-toxic and biodegradable magnetic nanoparticles (NPs) that can be easi y 
functionalized with drugs  or biomolecules and employed, under magnetic  fields, as targeted nano- 
carriers or components of scaffolds with on-demand functionalities, is a big challenge in the biomaterials 
research. ln the present work, the feasibility of previously synthesized iron-doped superparamagnetic 
apatite (FeHA) NPs to bind and then release the anticancer drug doxorubicin (DOX) under an applied low- 
frequency pulsed electromagnetic field (PEMF) was investigated. The behavior of FeHA towards DOX has 
been compared to that of synthetic biomimetic apatite (HA) NPs prepared ad hoc with characteristics 
close to those of bone minerai. The DOX adsorption kinetics and isotherms on FeHA and HA were 
explored and fitted according to different mathematical models (Elovich, Sips and Freundlich) revealing 
enhanced uptake of DOX on FeHA than HA due to the better interaction of the drug with the surface iron 
cations and formation of multi-molecular DOX assemblies. ln the absence of the PEMF, the quantity of 
DOX released from HA was higher than that released from FeHA in agreement with the lower affinity 
of DOX for HA than FeHA. lnterestingly, in the presence of the PEMF, the extent of DOX released from 
FeHA after 3 and 6 days increased significantly. The higher DOX release from FeHA under PEMF can be 
explained by the mechanical shacking of superparamagnetic FeHA NPs breaking the bonding with the 
drug and allowing detachment of DOX assemblies from the NP surface. ln vitro assays demonstrated that 
DOXloaded on HA and FeHA displayed cytotoxicity against the human osteosarcoma cell line (SAOS-2) at 
the same level as free DOX, for ail the concentrations and time points tested. Confocal microscopy 
analyses showed that drug-loaded NPs were rapidly internalized within cells and released DOX, which 
accumulated in the nuclei where it exerted the desired cytotoxic activity. 
1. Introduction
The use of nanosystems/nanoparticles (that will be described 
here by the generic abbreviation NPs) as drug carriers bas been 
widely explored during the last 20 years mainly to precisely 
administer therapeutic molecules in specific parts of the body 
with the final aim of improving their efficacy (enhancing their 
concentration at the site of interest and preventing early degra- 
dation and clearance) and reducing side effects.1•2 Different 
types of NPs (metallic, inorganic, polymeric, micelles, liposomes, 
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carbon nanotubes, etc.) have been evaluated as drug delivery 
systems particularly in cancer therapy, where serious drug side 
effects compromise the health of patients.3•4 
More recently, the use of magnetic NPs as drug carriers bas 
strongly emerged since they could be manipulated upon appli- 
cation of magnetic fields.5'6  In particular, the drug attached to 
magnetic NPs could be efficiently remotely controlled and targeted 
in desired areas of the body using external magnetic fields.7 
Moreover, magnetic NPs can also be employed for several other 
biomedical applications, such as cell labelling and separation,8
immunoassay,9 MRI contrast agents,10 and hyperthermia.11 
Recently, they were also used to prepare scaffolds for bone 
tissue engineering.12•13 In fact, under magnetic fields, these scaf- 
folds can provide on-demand release of drugs or biomolecules 
inducing osteogenesis and angiogenesis and at the same time 
magneto-mechanical stimulation on bone cells favoring prolifera- 
tion, differentiation  and bone healing.14•15
For biomedical applications, a required property of magnetic 
NPs is the superparamagnetism ,which is the ability to be strongly 
magnetized (i.e., the alignment of ail magnetic moments of atoms 
2
-, HP04 
4
-)
in parallel along the direction of magnetic fields) when they are 
exposed to low intensity magnetic fields, without having a 
remnant or residual magnetization when  the magnetic  fields 
are removed.16 This feature is necessary to avoid coagulation and 
agglomeration of NPs causing possible embolization of capillary 
vessels when they are used in vivo.17 
So far, magnetic NPs employed for biomedical applications 
are mainly based on super-paramagnetic iron oxide nanoparticles 
(SPIONs), consisting in mixtures of magnetite, maghemite and 
hematite,  which  have  been  demonstrated  successfully  both 
in vitro and in vivo.18 SPIONs can be synthesized with different 
morphologies, chemical compositions and magnetic properties 
but some limitations still exist including a low magnetic moment 
and low cargo capacity.19 In addition, although SPIONs are 
approved for human in vivo use by the American Food and Drug 
Administration (FDA),20 several concerns about their cytotoxicity 
have emerged.21•22 In fact, their chronic administration can lead 
to the accumulation of a high quantity of iron in soft tissues and 
organs such as liver and kidney, causing an imbalance in their 
homeostasis and even cytotoxic and inflammatory effects.23-25
To overcome the limitations of SPIONs, new forms of bio- 
compatible superparamagnetic NPs with a good magnetic moment, 
high drug loading capability and low iron content are strongly 
required. 
Hydroxyapatite (HA), whose stoichiometric composition 
corresponds to Ca10(P04)6(0H)z, is the most extensively used 
calcium phosphate phase in several biomedical fields because of 
its chemical similarity with the minerai phase of bone (composed 
of nanocrystalline non-stoichiometric carbonated apatites) and 
thanks to its the well-known properties like biocompatibility, 
biodegradability and pH-dependent dissolution.26 HA is mainly 
employed in bone tissue engineering in the form of scaffolds, 
injectable cements, coatings for metallic implants and in nano- 
medicine as NPs in suspension.26 Whether stoichiometric or not, 
HA is able to accommodate several substituting ions, while still 
maintaining its intrinsic structure.27'28 In particular, Ca2+  ions 
can be substituted to some extent by monovalent to tetravalent 
cations (e.g. from Na+, to Zn2+, Fe3+ and Ti4+), while P043- can be 
to its therapeutic potential against solid tumors.33 The chemo- 
therapy based on DOX, however, is limited by dose-dependent 
cardiotoxic side effects that can potentially lead to heart 
failure.33•34 To avoid this problem, targeted drug delivery could 
provide therapeutically effective DOX release directly at the 
tumor site improving the treatment of cancers. Moreover, DOX 
bas strong visible absorption and fluorescence emission, and 
therefore is one of the best molecules for pursuing the objective 
of this study, since its uptake and release from NPs can be easily 
monitored .35 
The behavior of FeHA towards DOX has been compared to 
that of iron-free biomimetic apatite nanocrystals prepared "ad 
hoc" with characteristics very close to those of bone minerai 
(denoted HA). The latter material, which bas already demon- 
strated high ability to bind and release several types of drugs 
such as tetracycline and bisphosphonates, 36'37 can be viewed as 
a biomimetic "golden synthetic standard" for bone minerai. 
The adsorption of bioactive molecules on the surface of bio- 
mimetic apatite (as opposed to simple impregnation) allows the 
formation of stable bonding with the nano-carrier. These pro- 
perties were attributed to the existence of a hydrated layer at the 
surface of biomimetic apatite nanocrystals containing mobile 
ions with a higher reactivity than those present at the surface of 
well-crystallized apatite. It thus allows a better control of the 
dose of the drug released for localized tailored therapeutic 
applications.38 Finally, the cellular uptake and cytotoxic 
activity of DOX-loaded FeHA and HA NPs were analyzed, as a 
proof of concept, in vitro in the human osteosarcoma (SAOS-2) 
cell line. 
2. Materials and methods
2.1 Materials 
Ammonium phosphate dibasic ((NH4)zHP04, ACS reagent), 
calcium hydroxide (Ca(OH)z, ACS reagent), calcium nitrate tetra- 
hydrate (Ca(N03}4H20, BioXtra), dimethyl sulfoxide (DMSO, 
(CH3)zSO, for molecular  biology),  doxorubicin  hydrochloride 
replaced by divalent (C03 2-), trivalent (As043-, V043-) (C27H2gN011·HCl, DOX, European Pharmacopoeia (EP) reference 
and tetravalent (Si04 anions.27'28 Recently Tampieri et al 29 have standard), HEPES sodium sait (C8H17N2Na04S, BioXtra), iron(n) 
developed biocompatible and biodegradable ionic substituted-HA 
NPs endowed with superpararnagnetic and hyperthermia features 
via doping HA with Fe2+/Fe3+ ions (denoted "FeHA"). Interestingly, 
even if the iron amount of FeHA NPs is significantly lower than 
that of maghemite and magnetite NPs, they are featured by 
comparable superparamagnetic properties and hyperthermia 
effect.29 In vitro studies have also demonstrated that FeHA NPs 
(alone or combined with poly(L-lactic) acid or poly(e-caprolactone)) 
positively influence osteoblast-like cells and mesenchymal stem 
cells  viability.30-32
The aim of the present work was, in essence, to evaluate the 
ability of superparamagnetic FeHA NPs to interact with the 
drug doxorubicin (OOX) (known also as adriamycin) monitoring 
the drug uptake and then the release over the time both in the 
presence and absence of an applied low-frequency electro 
magnetic field. DOX is commonly used in chemotherapies due 
chloride tetrahydrate (FeCl2·4H20, ReagentPlus®12), iron(m) 
chloride hexahydrate (FeC13·6H20, ACS reagent), isopropyl 
alcohol ((CH3)zCHOH, 299.7%, FCC, FG), phosphoric acid 
(H3P04, 285 wto/o in H20), nitric acid (HN03, ACS reagent, 70%), 
potassium chloride (KCl, BioXtra) and sodium bicarbonate 
(NaHC03, ACS reagent), thiazolyl blue tetrazolium bromide 
(MTI, C18H16BrN5S, BioReagent), trypan blue (C34H24N6014Sa4,
BioReagent) were purchased from Sigma-Aldrich and used as- 
received without any further purification. Dulbecco's modified 
Eagle's medium (DMEM F12), fetal bovine serum (FBS), 
Dulbecco's phosphate buffered saline (DPBS) without calcium 
and magnesium, penicillin -streptomycin, trypsin-EDTA, and 
4,6-diamidino-2-phenylindole dihydrochloride (DAPI) were 
purchased from Invitrogen Corporation (Carlsbad, USA) and 
used as-received without any further purification. The human 
osteosarcoma  cell  line  SAOS-2  was  purchased  from  ATCC 
(Manassas, USA). Ultrapure water (0.22 µS, 25 °C, Milli-Q, Millipore) 
was used in ail the experiments. 
2.2 Synthesis of superparamagnetic iron-substituted 
nanoccystalline apatite (FeHA) 
Superparamagnetic iron-substituted apatite (which will be referred 
to as "FeHA" in this study) was synthesized according to the 
method developed by Tampieri et al.29 Briefly, an aqueous 
solution of H3P04 (44.4 g in 300 mL) was dropped înto an 
aqueous suspension of Ca(OH)i (50.0 g in 400 mL) contaînîng 
FeCl2·4H20 (12.7 g) and FeCl3·6H20 (17.9 g) as sources of Fe2+
and Fe3+ ions, respectively, under constant heatîng and stirring 
at 40 °C. Once the neutralîzatîon reactîon was completed, the 
solution was kept under the same conditions used durîng the 
neutralization reactîon for 1h, and then left to age for 24 h at 
room temperature wîthout further stirrîng. The precipitate was 
separated from the mother liquor by centrifugation, washed three 
times with water by centrifugation and freeze-dried. The powder 
was then sieved (<125 µm) and stored in a freezer prior to use. 
2.3 Preparation of iron-free biomimetic nanoccystalline 
apatite (HA) 
The iron-free nanocrystalline apatite powder (which will be 
referred to as "HA" in this study) was prepared by a double 
decomposition technique at ambient temperature and close-to- 
physiological pH (7.47) by pouring an aqueous solution of 
Ca(Nü3)·4H20 (52.2 g in 750 mL) into a carbonate and phos- 
phate aqueous  solution  (165.8  g  of  (NH4)zHP04  and  9.0  g 
of NaHC03 in 1500 mL). The precipitate obtained was left to 
mature for one day at 50 °c, filtered, washed three times with 
deionized water and freeze-dried. The powder was then sieved 
(<125 µm) and stored in a freezer prior to use. 
2.4 Characterization of HA and FeHA 
The X-ray diffraction (XRD) patterns of the samples were 
recorded on a D8 Advance diffractometer (Bruker, Karlsruhe, 
Germany) equipped with a Lynx-eye position sensitive detector 
using Cu Kcx radiation (À = 1.54178 Â) generated at 40 kV and 
40 mA. XRD spectra were recorded in the 2e range from 10 to 
60° with a step size (20) of 0.02° and a counting time of 0.5 s. 
The crystallite sizes of HA and FeHA along the c-axis and the 
perpendicular  direction were estimated by applyîng Scherrer's 
formula39  using 2e = 25.8° and 2e = 39.7° diffraction peaks,
correspondîng to the (002) and (310) reflections, respectively. 
Fourier transform înfrared (FTIR) spectroscopy analyses 
were achîeved on a Nicolet 5700 spectrometer (Thermo Fisher 
Scîentifîc Inc., Waltham, USA) with a resolution of 4 cm-1by 
accumulation of 64 scans coverîng the 4000 to 400 cm-1range, 
usîng the KBr pellet method. 
Calcium, phosphate and  iron contents were  determîned 
by inductively coupled plasma optical emission spectrometry 
(ICP-OES) usîng a Liberty 200 spectrometer (Varian, Palo Alto, 
USA). An alîquot of 20 mg of sample was dîssolved in 50 mL of a 
1wt% HN03 solution prîor the analysîs. 
Carbonate titration was carried out by coulometry using a 
CM 5014 coulometer equipped with a CM 5130 acidification 
unît (VIC Inc., Joliet, USA). Ali chemîcal tîtratîons were asso- 
ciated wîth a relative error of about 1%. A BELSORP mini II 
apparatus (Mîcrotrac, Krefeld , Germany) (BET method based 
on nîtrogen adsorption) was used to determîne the specific 
surface area (SSAsET) of the samples. 
The sîze and (-potentîal were measured by dynamic light scatter- 
ing (DLS) using a Zetasizer Nano ZS (Malvem, Worcestershire, UK). 
NPs were suspended in 0.01 M HEPES buffer at pH 7.4 at a 
concentration of 0.1 mg mL-1. For size distribution measure- 
ments, low-volume quartz cuvettes (Hellma, Müllheim, Germany) 
were used. Ten runs of 30 s were performed for each measure- 
ment and four measurements were carried out for each sample. 
To evaluate the stability of apatite NPs and the corresponding 
DOX adducts in suspension, the derived count rate (cps) was 
recorded contînuously for 60 min. The (-potentîal was quantîfied 
by laser doppler velocimetry as electrophoretic mobility using 
disposable electrophoretic cells (Malvern, Worcestershire, UK). 
Twenty runs of 3 s were collected in each measurement. 
Transmission electron microscopy (TEM) observations were 
performed using a Tecnaî F20 (FEI, Hillsboro, USA) equipped 
with a Schottky emitter and operating at 120 keV.The instrument 
was also equipped with an energy dispersive X-ray spectrometer 
(EDX) for X-ray microanalysis on selected areas. The powder 
samples were dispersed in isopropyl alcohol, treated with ultra- 
sound and then a few droplets of the slurry were deposited on 
holey-carbon foils supported on a conventional copper microgrid 
(300 mesh). 
2.5 Drug adsorption and release experiments 
DOX adsorption experiments on apatitic substrates (HA and 
FeHA) were carried out usîng a constant solid-to-solution ratio 
corresponding to 20 mg of apatite in 5 mL of DOX solution at 
increasîng concentrations (0.1-5.0 mg mL-1). The amount  of 
DOX adsorbed (Qaas) for any data-point was determined by 
comparing the amount of DOX remainîng in solution after the 
adsorption experiment (supematant) to the initial concentration; 
DOX being directly titrated by visible spectrophotometry (absorp- 
tion at À = 496 nm) using a Cary Bio spectrophotometer (Varian, 
Palo Alto, USA). KCl 0.01M was used as a solvent in all experi- 
ments to provide a nearly constant ionic strength. A calibration 
curve (linear correlation factor of 0.9998) was previously drawn 
for standard solutions of DOX concentrations ranging from 0.001 
to 0.025 mg mL-1.
Adsorption experiments were carried out at 37 °C, placing 
vials in a horizontal settîng to ensure an optimal interaction 
between the surface of the apatite substrates and the solution. 
After the contact time was determined in a preliminary step 
(see the text), the system was centrîfuged (5000 rpm for 5 min) 
to allow retrieval of the solid and sampling of the supernatant 
for quantification of DOX. 
HA and FeHA functionalîzed with the maximum loading 
amount of DOX were analyzed by Raman mîcro-spectrometry, 
cross polarîzation magic angle spinning (CP/MAS) solid-state 
nuclear magnetic resonance (NMR), FTIR and DLS. 
Raman analyses were carried out on a confocal Labram 
HR800 micro-spectrometer, typically making observations in 
the range 400-4000 cm-1. The samples were exposed in back- 
scattering mode to a 633 nm He/Ne laser. The measurements 
were carried out with a spectral resolution of 3 cm-1• An optical 
objective x100 was used, conferring to the system a lateral 
resolution of 0.7 µm and an axial resolution of 2.7 µm. 
Solid-state cross-polarization magic angle spinning carbon- 
13 nuclear magnetic resonance experiments (CP/MAS -NMR) 
were performed on a Bruker Avance III 400 WB spectrometer 
operating at 9.4 T, 400 MHz, with Vr = 10 kHz (probe 3.2 mm), 
and an accumulation performed overnight. 13C chemical shifts 
were externally referenced to tetramethylsilane (TMS). 
FTIR and DLS analyses on the DOX loaded NPs were carried 
out as reported above for the un-functionalized NPs. 
DOX release experiments from HA and FeHA (previously 
functionalized with the maximum loading amount of DOX) 
were carried out at 37 °c in the presence or absence of a pulsed 
electromagnetic field (PEMF). Investigations in the presence of 
the PEMF were achieved placing the powder samples in an 
home-made device similar to that previously developed by 
Fassina et al.40 (Fig. Sl, ESit). Briefly, it consisted of a wind- 
owed polymethylmethacrylate tube carrying a well-plate con- 
taining the samples and two solenoids (i.e., Helmoltz coils, 
whose planes were parallel). The generated magnetic field and 
the induced electric field were perpendicular and parallel to 
the samples, respectively. Samples were 5 cm distant from each 
solenoid plane, and a Biostim SPT pulse generator (Igea, Carpi, 
Italy) was used to power the solenoids. According to the position 
of the solenoids and the characteristics of the pulse generator, 
the electromagnetic stimulus had the following parameters: 
intensity of the magnetic field equal to 2.0 ± 0.2 mT, amplitude 
of the induced electric tension equal to 5 ± 1mV, frequency of 
75 ± 2 Hz, and pulse duration of 1.3 ms. The samples were 
prepared using a constant solid-to-solution ratio corresponding 
to 5 mg of drug-apatite conjugate in 2.5 mL of HEPES buffer at 
pH 7.4 (0.01 M HEPES, 0.01 M KCl). At the scheduled times 
ranging from 1to 6 days, the temperature of the samples were 
measured (only those exposed to PEMF), centrifuged (5000 rpm 
for 5 min) to allow retrieval of the solid and sampling of the 
supernatant for quantification of DOX. The amount of DOX in 
the medium was determined by visible spectrophotometry as 
reported above. 
Dissolution of HA and FeHA in the presence and in the 
absence of a PEMF (using the same apparatus described above) 
was evaluated adding 10 mg of apatite in 10 mL of HEPES 
buffer at pH 7.4 (0.01 M HEPES, 0.01 M KCl). At scheduled 
times (up to 7 days), the supernatant (that was well separated 
from the solid phase by centrifugation) was removed, centri- 
fuged and filtered at 0.25 µm in view of Ca2+ quantification by 
ICP-OES. 
2.6 In vitro cell culture 
The human osteosarcoma cell line SAOS-2 was cultured in 
DMEM F12, 10% FBS and 100 U mL-l penicillin/streptomycin 
and kept at 37 °C in an atmosphere of 5% C02• The cells were 
detached from culture flasks by trypsinization, centrifuged and 
re-suspended. The cell number and viability were assessed by 
the trypan-blue dye exclusion test. For the experiments, the 
cells were plated at a density of 5 x 103 cells per well in 96-well 
plates, 24 hours after seeding the samples were added to the 
culture and the cells were maintained in culture for 24, 48 and 
72 hours. HA and FeHA loaded with similar amounts of DOX 
(475 and 449 µg of DOX on 1mg of HA and FeHA, respectively) 
were added to the culture at 10 and 100 µM concentration 
of attached DOX (Table Sl, ESit). Moreover, the equivalent 
amounts of un-functionalized HA and FeHA NPs used for each 
sample and free DOX were tested (Table Sl, ESit). A group of 
cells only was used as control group. The cells were incubated 
under standard conditions (37 °C, 5% C02). All cell-handling 
procedures were performed in a sterile laminar flow hood. 
2.7 Cell viability evaluation 
The MTT reagent (5 mg mL-1) was prepared in 0.01 M PBS. The 
cells were incubated with the MTT reagent 1:10 for 2 h at 37 °C. 
The medium was collected and cells incubated with 1mL of 
DMSO for 15 min. In this assay, the metabolically active cells 
react with the tetrazolium sait in the MTT reagent to produce a 
formazan dye that can be observed at absorbance max of 570 nm, 
using a Multiskan FC microplate photometer (Thermo Scientific, 
Waltham, USA). This absorbance is directly proportional to the 
number of metabolically active cells. The mean value of absor- 
bance was determined. The samples of three different experi- 
ments were analyzed in triplicate. 
2.8 NPs-DOX uptake and nuclear-localization 
After 24 hours, the cells were washed twice with 0.01 M PBS for 
5 min, fixed with 4% (w/v) paraformaldehyde for 15 min, washed 
with 0.01 M PBS for 5 min and incubated with DAPI for 7 min. 
The images were acquired using an inverted Ti-E fluorescence 
microscope (Nikon, Chiyoda, Japan). One representative field of 
each sample and the co-localization of the nuclear marker, DAPI, 
and DOX were analyzed. 
2.9 Statistical analysis 
The experiments were carried out in triplicate and the results 
were expressed as mean and standard error of the mean (SEM). 
Analysis of cell viability was made by two-way analysis of variance 
(ANOVA), followed by Bonferroni's post hoc test Statistical analyses 
were performed using the GraphPad Prism software (version 5.0), 
with the statistical significance set at p     0.05. 
3. Results and discussion
3.1 Chemical-physical  and morphological characteristics of 
FeHA and HA 
FeHA NPs exhibiting a saturation magnetization  of 4.00 ± 
0.01 Am2 Kg-1 and endowed  with a hyperthermia feature 
(temperature increase of about 40 °C in 60 s under an alternating 
magnetic field of 0.03 N A-1m-1at a frequency of 293 kHz) were 
synthesized according to the procedure reported by Tampieri 
et al.29 Iron-free biomimetic HA NPs were synthesized ad hoc 
to possess chemical-physical features (i.e. crystallinity degree, 
3 
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chemical composition, carbonate extent and morphology) similar 
to those of biogenic bone apatites. An adequate amount of 
carbonate species (employing NaHC03) were added in the reac- 
bands at ca. 560-603 (v4), 962 (v1), and 1000-1104 cm-1 (v3))45
(Fig. lB). The bands at 870 (v2), 1420 and 1470 cm-1(v3) assignable 
to C0 2- vibrations characteristic of mostly B-type carbonate- 
tion medium to synthesize HA with a similar carbonate extent apatite (i.e., C03 replacing P04  -)4 were also present in both
2
-
3 5 
to that present in bone apatite (3-6 wt%).26 Carbonate was also sampies. The bands assigned to C03 were more intense in 
included during the preparation of HA as a strategy to favor the 
formation of small NPs with a low crystallinity degree since 
carbonate ions are well-known inhibitors of apatite crystal 
growth and its incorporation leads to a reduction of the crystal- 
line order and dimensions.41•42
Both FeHA and HA exhibited similar XRD patterns, with broad 
and poorly defined peaks (which can be indexed according to the 
crystallographic features of hydroxyapatite, JCPDS no. 09-432) which 
are characteristics of bone nanocrystalline apatite (Fig. lA).43 The 
presence of the peak at 35.4° (corresponding to (311) plane of Fe304;
JCPDS no. 00-003-0863) in the XRD pattern of FeHA established the 
presence of a small amount of magnetite (2.6 ± 0.2 wt%)29 (Fig.lA). 
The mean crystallite sizes of FeHA and HA (Table 1), calculated 
along the (002) and (310) directions applying the Scherrer's formula, 
evidenced that both samples had the same crystallite dimen- 
sion along the plane perpendicular to the c-axis, while FeHA 
was composed of more elongated crystallites along the c-axis 
with a higher aspect ratio than HA. The lower aspect ratio (i.e. 
more isometric particles) of HA compared to FeHA was ascribed 
to the higher presence of carbonate ions inside the crystal 
lattice as already reported.42•44
The FTIR spectra of HA and FeHA revealed the typical bands 
of  poorly  crystalline  biomimetic  apatite  (i.e. P04 
A 
the case of HA as a more limited amount of carbonate, derived 
from the atmospheric C02, was adsorbed on the surface and/or 
entrapped in the lattice of FeHA during the synthesis. The 
carbonate extent in the FeHA and HA was quantified to be 
3.0 ± 0.1 and 1.5 ± 0.1wt%, respectively (Table 1). The Ca/P 
ratio of FeHA was remarkably lower (1.41 ± 0.03) compared 
to that of stoichiometric hydroxyapatite (1.67) because of a 
partial substitution of Fe2+ and Fe3+ for Ca2+ ions. The Ca/P 
ratio of HA was also noticeably lower (1.34), pointing to the 
non-stoichiometry of this compound and its similarity with 
bone apatite.26
The TEM images of FeHA showed needle-Iike crystals, rather 
heterogeneous in size, having dimensions of 10-30 nm in width 
and 70--100 nm in length mainly composed of smaller aggregated 
and isometric NPs of about 5-10 nm in width and 10-20 nm in 
length (Fig. lC). A very low concentration of dark spots (5-10 nm 
in size), corresponding to inclusions of Fe-rich phases as demon- 
strated by EDX analysis was also visible. EDX elementary analysis 
carried out in selected area of the FeHA sample containing and 
not containing the dark spots, revealed that the amount of iron in 
the area rich with black spots is much higher than that in the part 
without dark spots (Fig. S3, ESit). The TEM images of HA 
displayed elongated NPs having dimensions of 5-10 nm in width 
10 20 30 40 
Position (20') 
50 60 1800   1600 600 400 
Fig. 1 (A) XRD spectra, (B) FTIR spectra and (C and D) TEM images of FeHA and HA NPs. 
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Table 1 Bulk Ca/ P molar ratio, carbonate extent, mean crystallite size along c and ab-ax es (L002 and L310, respectively), specific surface area (SSA8ET),
(-potential and mean hydrodynamic radius (RH) of FeHA and HA NPs 
Sampie Ca/P ratio C03 (wt%) Loo2 (nm) L310 (nm) Ç-potential (mv) RH (nm) 
FeHA 1.41 ± 0.03 1.5 ± 0.1 18 ± 3 15 ± 3 44 ± 1 -17.6 ± 1.0 120 ± 2
HA 1.34 ± 0.02 3,0 ± 0.1 31 ± 5 18 ± 3 102 ± 1 -18.2 ± 1.3 74 ± 1 
and 20-30 nm in length (Fig. lD). HA NPs were less aggregated 
than FeHA presenting a higher specific surface area (SSAsET) 
(Table 1). The higher tendency of FeHA to form aggregates than 
HA was ascribed to the greater amount of foreign ions (i.e. Fe2+, 
Fe3+, C0 2-) causing crystal lattice distortion, reduction of the 
long-range periodic regularity, and possible modifications of 
surface energy.46 The higher structural disorder can induce the 
formation of quasi-amorphous parts, especially at the surface, 
causing junction  and adhesion of crystals by inter-crystalline 
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interactions during the synthesis or post synthesis under drying. 
The similar surface negative charge of FeHA and HA at pH 7.4 
(Table 1)was attributed to the existence of a hydrated surface layer 
(which is a peculiar feature of bone apatite and its biomimetic
counterpart) composed of disordered Ca2+, P043- and HP042-
o"'   2
o FeHA    - - -Elovich fit fOf FeHA kinetic data 
HA ···· Elovich fit for HA kinetic data
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ionic groups in non-apatitic structural environments, having an Fig. 2 Adsorption kinetics of DOX on (0) FeHA and <•J HA NPs. Separate
impact on the surface charge of the nanocrystals.47 However, it is 
worthwhile to mention that Ç-potential measurements only esti- 
mate the net surface charge of NPs, thus even if a negative value is 
recorded, this does not imply that only negatively charged sites 
are present on the NP surface. The mean hydrodynarnic radius 
(RH), calculated by DLS, of FeHA was larger than HA (Table 1) in 
agreement with the higher tendency of FeHA to form aggregates. 
The higher sizes determined by DLS in comparison to those 
quantified by TEM were consistent with the fact that TEM pro- 
vides information on individual NPs and the sample is dehydrated 
and immobilized on a solid support, and in contrast DLS gives 
the average of the hydrodynamic  size of an ensemble of dis- 
persed NPs.48
Ali the chemical-physical characteristics of the apatitic NPs 
reported above highlighted the biomimetic features of HA 
thanks to the evident morphological and structural similarities 
with bone apatite. FeHA NPs were primarily different from HA 
NPs in terms of chemical structure, surface area and tendency 
to form aggregates, while they had comparable surface charge 
and morphology. 
3.2  Adsorption of DOX on HA and FeHA 
The adsorption study was organized in two steps aiming, firstly, 
at inspecting the kinetics of adsorption, and secondly, at deter- 
mining the adsorption isotherms (at 37 °c). 
In the first stage, the adsorption kinetics of DOX on HA and 
FeHA substrates were investigated. The kinetic overview was 
made possible by following the amount of DOX adsorbed (Qaas) 
as a fonction of contact time between the inorganic substrate 
and the drug. The evolution of Qaas (given in µmol 
DOX m-2 apatite) versus time is plotted on Fig. 2 in the 
case of a constant DOX concentration of ca. 5 mmol 
L-1.
These data indicated that in both cases the adsorbed 
amount increased as a fonction of time, although in 
different ranges, 
8 
7 
6 
points are the experimental  data; dotted  lines indicate  Elovich fits of 
kinetic data. 
with a first rapid rise followed by a progressive stabilization: up to 
around 3.5 µmol DOX m-2 apatite ( 2 mg m-2) in the case of HA 
compared to a two-fold value of ca. 7 µmol m-2 ( 4 mg m-2) for FeHA. 
The shape of these kinetic curves points to a rather rapid adsorption 
of the DOX molecules, although faster for HA (around 200 min) than 
for FeHA (around 1000 min). The data have been tentatively fitted to 
the kinetic models often encoun- tered, namely the pseudo-first-order 
and pseudo-second-order as well as a general kinetic law of order 
"n'', and finally to the Elovich mode!, in a similar way as was done 
recently in the study of tetracycline adsorption on biomimetic 
apatite.36 Only the latter led to satisfactory correlation coefficients (R2
greater than 0.97) with R2 = 0.9766 for FeHA and 0.9945 for HA. In 
contrast, kinetic models of order "n" (including with n = 1and n = 2) led 
to uncorrelated data showing that the adsorption kinetics followed a 
more complex process. A relatively good fit (see dotted lines in Fig. 2) 
to the Elovich model, a logarithmic fonction of time, is often 
encountered for the adsorption of polyelectrolytes on heterogeneous 
surfaces.49'50
The molecular structure of DOX is represented in Fig. 82, ESI.t 
Itis composed of an (aromatic) anthracycline ring linked to an amino-
sugar: the pK value of the amino group was reported to be around 8.2,51'52 
while other pK values of the molecule (typically for -OH groups) were 
found to be beyond 9.5. This indicates that, under physiological 
conditions, the DOX molecule exists mainly in its acidic form, that is 
with a protonated amino group. The multiple oxygen atoms of the 
molecule offer on the other hand many polar groups (especially thanks 
to the conjugation of several double bonds and non-bonding doublets), 
but the hydro- gen atoms linked to the -OH groups of the molecule are 
expected to  remain  present  at physiological  pH  (7.4).  This  leads  to 
a 
3 6
situation where the DOX molecule exposes an -NH3+ group and 
several oxygen atoms providing multiple potential "interaction 
points" with apatite nanocrystals, despite the lack of anionic 
end-groups with well-known high affinity for apatitic surfaces 
such as phosphates, phosphonates or even carboxylates.53•54
This multiplicity of interaction sites on the DOX molecule 
may explain, in conjunction with the relative heterogeneity of 
the substrates, the relatively good fit with the Elovich equa- 
tion and the absence of any satisfying correlation with other 
kinetic models. 
The modeling of adsorption data over a  long  period  of 
time however poses  the potential issue of progressive modi- 
fications  of  non-stoichiometric  apatitic   substrates,   which 
can further mature or else undergo dissolution or partial re-
precipitation phenomena. In this study, we selected  the value 
of 90 min as the contact rime for the adsorption iso- therms to 
limit the significant post-maturation effect in the solids and  
dissolution. 
In the second stage, using this selected contact time, the 
adsorption isotherms of DOX on both FeHA and HA have been 
analyzed by performing experiments with increasing DOX con- 
centrations. Fig. 3 reports the obtained isotherms (at 37 °c 
in KCI 10-2 M) for Qaas expressed in µmol DOX m-2 apatite and 
Ceq (equilibrium concentration) in mmol 1-1• Interestingly, 
these two isotherms were found to exhibit distinct shapes. 
The different mechanisms of adsorption observed can reason- 
ably be attributed to the presence of iron within the apatite 
lattice as well as the small amount of a secondary iron oxide 
phase in the FeHA sample, thus leading to different types of 
accessible surface sites. 
In the case of the iron-free HA substrate, the isotherm curve 
showed a first steep increase of the amount of DOX adsorbed at 
an equilibrium concentration of up to Ceq 1 mmol L-i, 
followed by stabilization at greater concentrations. This general 
tendency points to an adsorption behavior with a progressive 
filling of surface sites and towards a maximal degree of cover- 
age. This type of evolution is noticed  in particular for the 
18 
Langmuir mode! and for the more general equation of Sips 
(Langmuir-Freundlich): 
Ks ·c 1
Qacts = Qm ·  1 + [(. .cm Sips isotherm
S eq 
which cornes back to the Langmuir model for the particular 
case of m = 1. In this equation, Qm designates the maximal 
adsorption coverage, Ceq is the equilibrium DOX concentration 
for the considered data-points, "m" is the Sips exponent, and 
Ks is the Sips constant. 
A mathematical analysis indicates that the adsorption data 
for the system HA-DOX can best be fitted with the Sips model 
(R2 = 0.9703) with Ks = 5.96 ± 3.27 and m = 1.7 ± 0.4. Despite a 
non-negligible  uncertainty,  the value  of  "m" appears to be 
noticeably distinct from unity, thus suggesting a neat departure 
from the standard Langmuirian case. A value of "m" greater 
than 1can suggest the existence of significant positive inter- 
actions (molecular cooperativity) of adsorbed molecules among 
each other.55•56 This situation was recently also encountered for 
the adsorption of other biomolecules on biomimetic apatites, 
such as tetracycline 36 and cytidine monophosphate ,57 but the 
maximal adsorbed amounts for these two moleculeswere signi- 
ficantly lower than the one observed here. As in the case of 
tetracycline, DOX molecules do not expose high-affinity end- 
groups for the surface of apatite; the amount of DOX adsorbed 
on HA is however  found to be particularly  high, reaching 
s µmol OOX m-2 apatite. lt suggests a rather high affinity of
DOX for apatitic substrates, in agreement with a preliminary work 
indicating the value 8.2 µmol m-2,58 but in contrast to what could 
have been expected from such molecules without specific high- 
affinity end-groups for apatite surfaces. The range of adsorbed 
quantities can be compared to other adsorption data obtained for 
rather similar conditions/substrates. For example, the maximal 
adsorbed amount reached ca. 2.7 µmol m-2 for the adsorption of 
tiludronate (an anti-osteoporotic bisphosphonate compound) on 
carbonated nanocrystalline apatite,37'59 or else 2.4 µmol m-2 for 
platinum bisphosphonate complexes.60 The observation of a high 
affinity of DOX for the apatitic surface is surprising taking into 
account the absence of known high-affinity anionic end-groups 
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such as phosphates, phosphonate s or carboxylates, and also in 
comparison with the adsorption of tetracycline which led to a 
maximal coverage of 0.66 µmol m-2 (on a carbonated apatite 
matured for 1week at room temperature) .36 DOX molecules are 
expected to interact with apatite surfaces mostly through their 
multiple polar sites, but these sites are also susceptible to allow 
interactions among neighboring DOX molecules for a coopera- 
/ 
.../
a 4 ;, 
tive adsorption, as already suggested by the value of the Sips 
parameter "m". 
.J"' -o   Fe_H_A F_reundlich-isotherm_f_or_F_eH-A  data DOX  molecules  however  present  an important peculiarity 
'.' HA Sips isotherm for HA data 
o .......
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Fig. 3 Adsorption isotherms of DOX on FeHA (0) and HA (•). Separate 
points are the experimentaldata; dotted lines indicate Freundlich and Sips 
fits of isotherm data for FeHA and HA. respectively. 
over other molecules tested so far in adsorption experiments 
involving apatites: these water-soluble molecules are indeed 
composed of a large hydrophobie anthracycline ring composed 
of 4 coplanar carbon cycles (see Fig. S2, ESit), attached to a 
smaller hydrophilic side chain. In this context, hydrophobie/ 
hydrophilic  properties  are expected  to  significantly  affect  the 
2
0behavior of DOX molecules in aqueous-based experiments.61
The presence of this large planar aromatic portion of the mole- 
cules is at the origin of the therapeutic activity of DOX via inter- 
calation within DNA strands. Several studies have pointed out the 
possibility for DOX molecules to self-assemble, forming dimers, 
trimers or even much larger polymolecular units.52•61•62 This type 
of molecular interaction between DOX molecules is believed 
to involve n-n stacking processes of their coplanar aromatic 
domains;61 and both parallel and antiparallel stacking can be 
considered between interacting DOX molecules.62 Such strong 
molecular interactions/stacking (dictated by optimal spatial 
distribution of hydrophobie and hydrophilic parts of the mole- 
cules) are also likely to occur in an adsorption context, where 
the molecules are contacted not only with an aqueous solution 
but also with a solid surface. This phenomenon could indeed 
explain the exceptionally high adsorbed amounts noticed for the 
HA-DOX system compared to the case of other organic mole- 
cules: instead of having only individual "monomeric" DOX 
molecules adsorbed on the apatitic surface, strongly-interacting 
molecules could organize in a stable manner on the surface of 
the solid and among each other, leading to what could be finally 
considered as a "high affinity" system with favored basal and 
lateral interactions. The fact that the HA-DOX isotherm reaches a 
stabilized plateau indicates that the adsorption process finally 
leads to a DOX-saturated surface where no further molecules can 
be added (at this temperature), and the relatively good fit to the 
Sips model suggests that, at least macroscopically, the adsorption 
process can be satisfactorily treated by considering the adsorp- 
tion of initially monomeric DOX with significant cooperativity 
between adsorbed DOX molecules (although the exact orienta- 
tion and  positioning of the species cannot  be  categorized  at 
this point). 
The Sips affinity constant Ks (recalculated for Ceq expressed 
in mol L-1) is itself related to the standard Gibbs free energy 
(  G:ds) of the global adsorption process by the relationship: 
Ks = exp (RG ds) 
when applied to the present HA-DOX system, this equation leads 
to   G:ds -35 kJmoJ-1• Although this value relates to standard 
conditions, it allows comparisons with the same property for other 
adsorption systems. It is in particular more negative than the 
Gs values estimated for the systems tetracycline/apatite 36 and 
cytidine monophosphate/apatite 57 (of the order of -20 kJ mol-1),
indicating a more energetically favorable process. These findings 
are in agreement with the above experimental results and discus- 
sion, pointing out high adsorbed amounts and strongly suggest- 
ing the existence of interactions between DOX molecules. 
In the case of the FeHA, even greater adsorbed amounts were 
observed compared to HA, and the shapes of both isotherms were 
significantly different (Fig. 3). When expressed in µmol m-2, the 
adsorbed amounts achieved for FeHA appear to be somewhat 
lower than the values obtained for HA only up to an equilibrium 
concentration of ca. 1.5 mmol L-1; beyond this concentration 
limit, the adsorbed  amount continues however  to increase 
without stabilizing in the rather large concentration window 
1.5-7 mmol L-1•  The values  of  Nads  achieved  here  (up to 
18 µmol m-2 when expressed per unit surface area) are parti- 
cularly high for apatitic surfaces and especially in comparison 
to the adsorption data obtained previously on the HA substrate. 
In both cases (FeHA and HA), the formation of multi-molecular 
DOX assemblies adsorbed has to be considered to explain these 
observations, as was developed above for the HA-DOX system, 
but the significant further increase observed for FeHA can only 
be assigned to the presence of iron doping (as iron-substituted 
apatite but also as small percentage of iron oxide secondary 
phases, see Fig. 1), thus providing additional adsorption sites. 
In solution, the presence of divalent and trivalent ions was 
shown to favor the interaction among DOX molecules towards 
the formation of multimolecular self-assemblies, and the case of 
Fe3+ was particularly noticed:61 quelamycin (triferric doxorubicin) 
is a derivative of DOX exploiting this specificity of iron-DOX 
interaction.63-65 The good affinity of DOX for iron cations is 
thus likely to play a large part in the greater adsorbed amount 
noticed for FeHA-DOX in comparison to HA-DOX. 
The mathematical modeling of the FeHA-DOX adsorption 
isotherm is delicate because various types of adsorption sites 
coexist, in the form of separate crystalline phases. The overall 
adsorption process is thus composed of superimposition of 
various adsorption phenomena involving the various types of 
surface sites accessible to DOX molecules. In this context, the 
global isotherm corresponds to a sum of events and should only be 
seen as a "macroscopic" result. However, being able to describe it 
mathematically could prove to be useful, from a practical view- 
point, for example for being able to estimate the amount of DOX 
molecules susceptible to adsorb on such a substrate in a given 
concentration scenario. The application of the Sips mode!did not 
allow here a good description of the FeHA-DOX data without very 
large uncertainties on Sips parameters. This can be related to the 
coexistence on this sample of different crystalline phases with 
distinct adsorptive behaviors. The mathematical modeling of 
the global FeHA-DOX isotherm using Freundlich's equation 
(Qads = KF.Ceq11n) led, on the contrary, to a satisfactory overall fit, 
with a value of "n" of 1.7 ± 0.1and a correlation coefficient of 
R2 = 0.9919. Freundlich's model has initially been established 
for explaining adsorption data on non-equivalent  adsorption 
sites corresponding to a range of adsorption energies (rather 
than a constant value as is the case in Langmuir's theory). The 
goodness of fit noticed here with the Freundlich model prob- 
ably arises from the existence, in the FeHA substrate, of a series 
of adsorption sites with a non-negligible span in energy. Even if 
it is not possible at this stage to give more detail on the type of 
interaction existing between the multi-phased FeHA  sample 
and DOX nor between adjacent DOX molecules, this mathema- 
tical modelling at least allows one to satisfactorily describe the 
overall evolution of Qads versus Ceq·
3.3 Characterization of HA and FeHA functionalized with 
DOX 
In order to get more information on the interaction mechanism of 
DOX with HA and FeHA and to evaluate how the functionalization 
can affect the surface properties  and the size of the NPs, the 
Ç-potential and mean RH of the HA and FeHA functionalized with 
the maximum amount of DOX were measured. The coupling of 
20,- c===o====;-i 
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HA and FeHA with DOX altered their surface charge, in parti- 
cular this functionalization caused a shift of the Ç-potential of 
HA and FeHA (-5.6 ± 2.0 and -8.1 ± 3.5 mV, respectively) 
toward less negative values. This finding is in agreement with a 
possible interaction of the positively charged -NH3+ groups of 
the DOX dimers with the negatively charged surface groups of 
apatites (i.e. phosphates, phosphonates or even carboxylates) as 
reported above. The surface uptake of DOX provided the NPs 
with a less negative surface charge, which in turn also decreased 
the inter-particles repulsion. Consequently, HA-DOX and FeHA- 
DOX were  more  aggregated, forming less stable  suspensions 
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than the bare ones with increased mean RH of 281 ± 24 and 
354 ± 52 nm, respectively. The stability in an aqueous suspen- 
sion of bare and functionalized NPs (0.1mg mL-1) as a function 
of time bas been evaluated by DLS, measuring continuously for 
60 min the derived count rate (Fig. S4, ESit). In the case of HA 
and FeHA, the recorded values remained nearly constant, corro- 
borating that neither significant aggregation nor fast sedimenta- 
tion occurred. On the contrary, in the case of functionalized NPs 
the fast decrease of the derived count rate revealed their lower 
stability in suspension. 
Comparison of the FTIR spectra of FeHA-DOX, HA-DOX and 
free DOX (Fig. SS, ESit) was not useful to shed some light on the 
interaction mechanisms of DOX molecules with the inorganic 
phase. Nevertheless, the appearance of the DOX main signal at 
1284 cm-1 (c-o-c asymmetric stretching66) in the spectra of 
FeHA-DOX and HA-DOX confirmed the effective uptake of the 
drug on the NPs. 
Raman microanalyses were run on the solids after DOX 
adsorption, but no useable data on the position of bands and 
eventual shifts were obtained due to strong fluorescence artifacts 
from DOX with the employed laser wavelength at our disposai 
(Fig. S6, ESit). Moreover, 13C CP/MAS solid-state NMR analyses 
were tentatively run to observe the interaction of DOX molecules 
with the surface of apatite nanocrystals. However, although the 
recorded signais can be well correlated to the presence of DOX 
(Fig. S7, ESit), they only showed a low-intensity noisy signal not 
exploitable for drawing conclusive statements on the chemical 
interaction of the drug with the apatitic substrate, which can be 
linked to the limited amount of DOX on the samples and low 
isotopie abundance of 13C. 
3.4 Release of DOX from HA and FeHA 
HA and FeHA were functionalized with similar amounts of DOX 
(i.e. 475 and 449 µgof DOX on 1mg of HA and FeHA, respectively) 
corresponding to the maximum drug loading capacity of HA. 
The DOX release efficacy (DR) from drug-loaded HA and FeHA, 
defined as the ratio (wto/o) between the amount of drug released 
at different times (QctJ) and the initial drug loading capacity Qii 
was calculated using the following formula: 
Fig. 4   Kinetics of DOX release from HA and FeHA in the absence or 
presence of a pulsed electromagnetic field (PEMF). 
DR of DOX from HA and FeHA as a function of time under near 
physiological conditions (pH 7.4) and in the absence or pre- 
sence of a PEMF is shown in Fig. 4. In the absence of the PEMF, 
the percentage of DOX released from HA was higher than that 
released from FeHA. DOX was gradually released from HA as a 
function of time reaching after 6 days the value of about 15 wto/o 
of the initial DOX loaded. On the contrary, the maximum 
amount of DOX released from FeHA in the absence of the PEMF 
(about 3 wto/o of the initial DOX loaded) was achieved after 2 days 
since no significant difference was found with the drug released 
after 3 and 6 days. The lower amount of drug released from FeHA 
with respect to HA is in good agreement with the higher affinity 
of DOX for FeHA, as already mentioned in the discussion on the 
adsorption  isotherms. 
Generally speaking, the relatively low amounts of DOX released 
from HA and FeHA at pH 7.4 are in agreement with the data pre- 
viously reported in other studies58'67 and confirm the strength of 
the bonding between the apatite substrate and the drug molecules. 
The possibility to move FeHA NPs (and even entire cells after their 
internalization) upon the application of a static magnetic field of 
320 mT (Fig. SS, ESit) bas been recently reported,68 corroborating 
their potential ability to be targeted in specific body systems by 
magnetic fields. The high affinity of FeHA towards DOX and the 
low amount of the drug released at pH 7.4 points out that even 
FeHA-DOX could be guided without any concomitant Joss of the 
therapeutic agent. 
Magnetic NPs can be directed  by  static  magnetic  fields, 
but also provide remote controlled release of drugs or bio- 
molecules, i.e. in scaffold formulation by magnetic stimulation. 
Therefore the release of DOX from FeHA, in comparison with 
that from  HA,  has been evaluated applying a low frequency 
PEMF. Interestingly, in the presence of the PEMF, the extent of 
DOX released from FeHA after 3 and 6 days increased signifi- 
cantly (3.5 ± 0.3 vs. 7.0 ± 1.0 wto/o after 3 days and 3.7 ± 0.1vs. 
10.0 ± 1.0 wto/o after 6 days, in the absence and presence of the 
PEMF, respectively). This increase was directly related to the 
superparamagnetic feature of FeHA, since no statistical differ- 
ence between DOX released from HA in the presence and in 
absence of the PEMF was observed. 
Itwas well demonstrated in the last years that upon applica- 
tion of an alternating electromagnetic field, superparamagnetic 
NPs could generate local internai heating, causing structure 
disassembling and allowing the cargo (drug) to be released.69•70
In order to assess if a similar effect bas been exhibited in this 
work, dissolution of FeHA in the presence or absence of a PEMF 
was monitored. The extent of released Ca2+, which  can be 
considered as an index of the FeHA dissolution, was quantified 
after 3 and 6 days (Fig. S9, ESit). No significant differences were 
observed between the amounts of Ca2+ released in the presence 
or absence of the PEMF, indicating that the increase of DOX 
released was not triggered by a more rapid degradation of the 
carriers. Moreover, during the PEMF exposure, FeHA suspen- 
sion did not show any significant increase in temperature in 
the bulk solution. The PEMF used in this work was of low 
frequency comparable to that commercially used to stimulate 
and activate bone healing71 and according to previous magnetic 
characterizations,29 it was too weak to induce a hyperthermia 
effect on FeHA. Therefore, the higher release of DOX from FeHA 
in the presence of the PEMF can presumably be explained by 
the mechanical movement (i.e. shaking and flipping) of super- 
paramagnetic NPs breaking the bonding with the drug or 
allowing detachment of multi-molecular DOX assemblies from 
the NPs surface, rather than the destabilization of the crystal 
structure or the increase of temperature. This hypothesis is 
coherent with the fact that the appreciable differences of drug 
release in comparison to the experiments carried out without the 
PEMF were evident only at long time points (i.e. 3 and 6 days) 
when the strong bonding between the drug and NPs was weakened 
by the continuous pulsed stimulation. 
The DOX release kinetics data obtained for both HA and 
FeHA (whether in the absence or presence of the PEMF) were 
analyzed from a mathematical viewpoint by fitting with several 
release models (zero order, first order, gas-like desorption, 
Higuchi, Korsmeyer-Peppas (KP) and Hixson-Crowell (HC) models), 
described in the literature.72-74 A screening of these models was 
done using their linearized forms and considering the same 
number of data points to get comparable R2 correlation coeffi- 
cients based on the same number of  degrees  of  freedom 
(the origin (O;O) was omitted here due to logarithmic calcula- 
tions tending to infinicy in some of the models). The obtained 
correlation coefficients are listed in Table S2, ESI.t The results 
systematically indicate that the diffusion-based models, i.e. 
Higuchi and KP models, were the most appropriate to fit the 
experimental release data among the models tested. In con- 
trast, only a poor correlation was found for gas-like desorption 
(the model supposing a low adsorbent-adsorbate affinicy) or 
the matrix-dissolution mode] like the HC model. These results 
suggest that the release kinetics of DOX from HA or FeHA are 
mainly controlled by DOX diffusion from the substrate (inter)- 
granular surfaces/spaces up to the solution rather than by the 
progressive dissolution of the substrates (which is indeed 
expected to be limited at physiological pH). The KP model is 
described by a power law of the form DR = k·f' where DR is the 
cumulative release described above, "t" is the time, and "k" 
and "n" are constants (the Higuchi model being a special case 
of the KP model with n = 0.5). The exponential factor "n" was 
found to vary in the range 0.29-0.86 (Table S2, ESit). Except for 
the unusually low value of 0.29 (lower than 0.5 and thus probably 
not representative), ail other cases fall in the 0.5  n  1.0 
domain often considered as "anomalous transport", corres- 
ponding to complex release mechanisms with non-Fickian dif- 
fusivicy. A similar situation was for example found in the case of 
vancomycin release from  brushite.75 It may be noted that no 
clear trend allows here distinguishing the release mechanisms of 
the different conditions studied (HA or FeHA; with or without 
PEMF application); only the amount of DOX released seems to 
be affected. 
3.5 In vitro cell culture 
Assessment of SAOS-2 cell viabilicy grown in contact with 10 
and 100 µM of DOX, either free or loaded onto HA and FeHA 
NPs, as well as with equivalent amounts of un-functionalized 
NPs, was carried out by quantification of metabolically active 
cells by the use of the MTT assay.76  The results indicated that 
the DOX, loaded on HA and FeHA, was able to exert its cytotoxic 
activicy on SAOS-2 cells. In fact, HA-DOX and FeHA-DOX, at all 
the concentrations tested (Table Sl, ESit), showed reduced cell 
viabilicy compared to the sample with only cells, with statistic 
differences after 48 and 72 hours of culture (Fig. 5). Moreover, 
no significant difference existed between the cytotoxic effect 
exerted by DOX free or loaded on HA and FeHA NPs at all the 
concentrations and each time points tested (Fig. 5) indicating 
that the bonding with the NPs did not affect the DOX antitumor 
activicy. 
It is well reported that the calcium phosphate NPs can be 
internalized inside cells via clathrin- and caveolae-dependent 
endocytosis,77 while free DOX can diffuse through the plasma 
membrane due its lipophilic properties.78 Here, the nuclear 
localization of the different DOX-loaded HA and FeHA was 
evaluated by fluorescence microscopy. Fig. 6 and 7 show DOX 
internalized without any difference among the groups. lt was 
also possible to observe a higher intensicy of fluorescence in 
both HA-DOX and FeHA-DOX 100 µM groups (Fig. 6 and 7A-C) 
compared to 10 µM groups (Fig. 6 and 7D-F), indicating a 
dose-dependent drug internalization. Moreover, in agreement 
with the data previously reported,58'67 under all the tested 
conditions, after 24 hours DOX was mainly detected within 
the nuclei. 
On the basis of our previous data and those described in 
others studies about the internalization of calcium phosphate 
NPs inside cells,58'67'79•80 and taking into account that the 
bonding between DOX and HA/FeHA NPs was stable under 
physiological conditions, it is realistic to assume that DOX-loaded 
NPs were easily and rapidly internalized by cells and able to carry 
inside their bound DOX. Once inside the cells, DOX can be 
released from the NPs where the slightly acidic conditions of 
lysosomes allowed faster degradation of FeHA and HA NPs.58•67•68
After that, DOX diffused into cell nuclei and induced DNA 
damage exerting its cell apoptosis effect. 
Severa!studies reported that at initial stages free DOX is 
more effective than that attached to the iron oxide NPs due to 
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Fig. 5 Analysis of SAOS-2 cell line viability by the MTT assay, after 24, 48 and 72 h of culture with 10 and 100 µM of DOX either free or loaded on (A) HA 
and (B) FeHA NPs,as well as with equivalent amounts of un-functionalized (A) HA and (B) FeHA. The sample with only cells was used as the contrai. The 
graph shows the average and standard  deviation of 6 replicates; statistical significant differences among the samples are indicated in the graphs: 
*p     0.05, **p     0.01and ***p     0.001. 
Fig. 6 Analysis of the internalization of HA-DOX NPs in the SAOS-2 cell line alter 24 h of culture by fluorescence microscopy. Images A B and C show 
DAPI nuclear staining (blue). nuclear localization of DOX (red) and merge of the co-localization of DAPI and DOX for the sample HA-DOX 100 µM. 
Images D, E and F show DAPI nuclear staining (blue). nuclear localization of DOX (red) and merge of the co-localization of DAPI and DOX for the sample 
HA-DOX 10 µM. Scale bars 100 µm. 
the different mechanism of cellular uptake.81•82 Free DOX 
passes from the extracellular to the intracellular matrix by 
simple passive diffusion and reaches the nuclei easily, while in 
the case of iron oxide NPs-bound DOX, the drug is released from 
the NPs surface in lysosomes due to the acidic pH environment 
and hence DOX can reach the nuclei and intercalate DNA. The 
fact that in our case DOX coupled to apatitic NPs displayed 
comparable cytotoxicity of free DOX at all the time points was 
correlated with the fast internalization process and the rapid 
degradation of FeHA and HA in the lysosomal compartments 
respect to iron oxide NPs. 
In vitro tests with cells in the presence of a PEMF were not 
carried out because the time of the magnetic field to trigger an 
higher drug release from FeHA (3 days) was not comparable 
to that of cell internalization (few hours), therefore any effect 
would be further appreciated. 
""'
Fig. 7 Analysis of the internalization of FeHA-DOX NPs inthe SAOS-2 cell line after 24 h of culture by fluorescence microscopy. Images A, B and C show 
DAPI nuclear staining (blue). nuclear localization of DOX (red) and merge of the co-localization of DAPI and DOX for the sample FeHA-DOX 100 µM. 
Images D, E and F show DAPI nuclear staining (blue), nuclear localization of DOX (red) and merge of the co-localization of DAPI and DOX for the sample 
FeHA-DOX 10 µM. Scale bars 100 µm. 
4. Conclusions
In this work, the effective ability of previously synthesized 
superparamagnetic FeHA29 to load DOX was demonstrated. 
FeHA displayed higher affinity for DOX in comparison to 
iron-free biomimetic HA NPs due to good affinity of the drug 
for the iron cations of the FeHA surface. The stability of the 
bonding between DOX and FeHA was stronger compared to HA; 
in fact, the quantity of DOX released at pH 7.4 from FeHA was 
lower than the drug released from HA. The release of DOX 
from FeHA was also assessed in the presence of a PEMF, and 
fascinatingly the extent of DOX released after 3 and 6 days 
under these conditions increased significantly in comparison 
to the drug release without a PEMF. This finding was explained 
by the mechanical shacking of superparamagnetic NPs break- 
ing the bonding with DOX or allowing detachment of drug 
assemblies from the NPs surface, rather than by some higher 
degradation of NPs or a temperature increase. Finally, in vitro 
assays demonstrated that DOX loaded on HA and FeHA was 
able to exert its cytotoxic activity on SAOS-2 cells at the same 
level as free DOX, for all the concentrations and time points 
tested, because the functionalized NPs can be rapidly inter- 
nalized within cells and release DOX, which accumulated in the 
nuclei and exerted cytotoxic activity. 
In light of our results and taking into account that the 
biocompatibility of FeHA particles, their pH-dependent bio- 
degradability and ability to be moved by an external magnetic 
field were already demonstrated, 29•30•68 and although further 
in vitro and in vivo studies are necessary, we can conclude that 
this new superparamagnetic nanosystem can represent a novel 
alternative to SPIONs to set up magnetic devices for stimulating 
personalized nanomedical applications such as targeted drug 
nano-carriers and scaffolds for bone tissue engineering with 
remotely controlled multi-functionalities. 
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